The Incit teams
Team 3
Anti-tumour immunosurveillance and immunotherapy
Objectives of the research programs
Our projects aim to elucidate the mechanisms involved in the regulation of immune responses in human solid tumours, to identify new therapeutic targets, to develop and optimise anti-tumor and anti-viral immunotherapy strategies, and to identify early markers of response to these treatments.
Research projects
Our work is organised around 4 main interrelated programs focusing on
- the characterization of shared tumor-specific antigens derived from dysregulated translation mechanisms or defects in the antigen presentation machinery. These types of antigens constitute new relevant targets for anti-tumor immunotherapy. Coordinated by F. Lang, C. Rabu, N. Gervois, H. Benlalam.
- Regulation of anti-tumor T cell responses within the microenvironment, particularly through immune checkpoint signaling pathways, as well as innate immunity pathways, including tumor cell inflammasomes. Coordinated by A. Jarry, H. Benlalam, N. Gervois.
- The development and optimization of immunotherapy strategies, particularly adoptive transfer strategies of T lymphocytes specific for tumor epitopes (from melanoma and colorectal cancer) and viral epitopes (HIV), by optimzing lymphocyte functions using genome editing methods. Coordinated by N. Labarriere and B. Monel
Our team is part of the LabEx ImmuNE program of excellence LabEx ImmuNE (Immunology-Nantes-Excellence) program, and our research programs have been certified by the National League Against Cancer (2022-2026).
Graphic summary
Highlights
Dupré et al. Systematic identification of lincRNA-derived immunogenic peptides in melanoma. OncoImmunology, 2025
Dupré et al. Oncoimmunology 2025
Cadiou et al. Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes. OncoImmunology, 2024
Themes addressed
Anti-tumor T cell responses: characterization of immune subpopulations and regulation by the microenvironment
Coordinated by N. Gervois, H. Benlalam, and A. Jarry
Identification and characterization of target antigens for immunotherapy in melanoma and colorectal cancer
Coordinated by F. Lang, N. Gervois and C. Rabu
Optimization of T cell functions for adoptive cell transfer (Cancer and viral infections).
Coordinated by N. Labarriere and B. Monel
The team
3 researchers
5 teacher-researchers
1 post doc
- U. Hirigoyen, post-doc
8 ITA
- T. Beauvais, AI
- Mr. Laporte, IA
- C. Deleine, AI
- S. Lambot, AI
- N. Mennesson, TC
- Z. Pineau-Grimaud, AI
- A. Boucard, IE
- Mr. Ahondo, IE
7 doctoral students
Scientific publications
Find the major publications of the team of the last 2 years
Systematic identification of lincRNA-derived immunogenic peptides in melanoma.
Dupré E., Guiho A., Beauvais T., Labous L., Cardon T., Bertolotto C., Khammari A., Quéreux G., Salzet M., Labarrière N., Rabu C., Lang F.
Oncoimmunol. 2025 Feb;16(1). doi.org/10.1080/2162402X.2025.2538684
Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T lymphocytes.
Cadiou G., Beauvais T., Marotte L., Lambot S., Deleine C., Vignes C., Gantier M., Hussong M., Rulli S., Jarry A., Simon S., Malissen B., Labarriere N.
Oncoimmunol. 2024 13(1). doi.org/10.1080/2162402X.2024.2376782
hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote MELOE-1 translation in stressed melanoma cells.
Charpentier M, Dupré E, Fortun A, Briand F, Maillasson M, Com E, Pineau C, Labarrière N, Rabu C, Lang F.
Mol Oncol. 2022 Feb;16(3):594-606. doi: 10.1002/1878-0261.13088.
Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer.
Ducoin KOger R, Bilonda Mutala L, Deleine C, Jouand N, Desfrançois J, Podevin J, Duchalais E, Cruard J, Benlalam H, Labarrière N, Bossard C, Jarry A, Gervois-Segain N.
OncoImmunoly. 2022 Tue 09; doi.org/10.1080/2162402X.2022.
The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer.
Mutala LBDeleine C, Karakachoff M, Dansette D, Ducoin K, Oger R, Rousseau O, Podevin J, Duchalais E, Fourquier P, Thomas WEA, Gourraud PA, Bennouna J, Brochier C, Gervois N, Bossard C, Jarry A
Cancers (Basel). 2021 Jan 7;13(2):189. doi: 10.3390/cancers13020189.
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L, Simon S, Vignard V, Dupre E, Gantier M, Cruard J, Alberge JB, Hussong M, Deleine C, Heslan JM, Shaffer J, Beauvais T, Gaschet J, Scotet E, Fradin D, Jarry A, Nguyen T, Labarriere N.
J Immunother Cancer. 2020 Jan;8(1):e000311. doi: 10.1136/jitc-2019-000311. PMID: 32001504 Free PMC article.
Cancer Vaccines: Designing Artificial Synthetic Long Peptides to Improve Presentation of Class I and Class II T Cell Epitopes by Dendritic Cells.
Rabu C, Rangan L, Florenceau L, Fortun, A.; Charpentier, M.; Dupré E, Paolini L, Beauvillain C, Dupel E, Latouche J.-B, Adotevi O, Labarrière N, Lang F.
Oncoimmunology 2019, 8 (4), e1560919. doi: 10.1080/2162402X.2018.1560919
Contact
Contact
Nathalie LABARRIERE
nathalie.labarriere@univ-nantes.fr
Website
Nantes
Location
IRS2, Nantes University
22 Boulevard Benoni Goullin
44200 Nantes
About us
Created in 2022, the INCIT(Immunology and New Concepts in Immunotherapy) research unit, directed by Frédéric Altare, is based on the desire to focus thescientific expertise of the immunology and immunotherapy teams on different pathological contexts: inflammation, cancer and infectious diseases.